The effects of Mixodin supplementation on migraine headache characteristics, oxidative stress and inflammatory biomarkers in patients with migraine: a double-blind, placebo-controlled, randomized trial
Abstract
BACKGROUND: Migraine is a prevalent neurological disorder closely linked to oxidative stress and neurogenic inflammation. Curcumin, gingerol, and piperine are natural compounds with well-established anti-inflammatory and antioxidant properties; however, clinical evidence on their combined effects in migraine remains limited. AIM: This study aimed to evaluate the effects of eight weeks of Mixodin supplementation on inflammatory and oxidative stress biomarkers, and clinical migraine characteristics, in patients with migraine. METHODS: This randomized, double-blind, placebo-controlled trial enrolled 60 patients with migraine, who were randomly assigned to receive two Mixodin capsules daily (each containing 300 mg curcumin, 7.5 mg gingerol, and 3.75 mg piperine) or placebo for eight weeks. Serum hs-CRP, NO, MDA, TOS, TAC, and SOD were measured before and after the intervention. Headache severity, frequency, and duration were recorded using VAS and a headache diary. RESULTS: Mixodin supplementation significantly reduced serum Hs-CRP (− 0.87 ± 0.19 vs. − 0.16 ± 0.09 mg/L; P = 0.001) and NO levels (− 5.53 ± 1.53 vs. + 3.51 ± 1.79 µmol/L; P = 0.042) compared with placebo. Additionally, eight weeks of Mixodin supplementation resulted in a trend toward increased SOD activity and TAC, and a trend toward decreased TOS; however, these changes did not reach statistical significance when compared with the control group (all P > 0.05). No significant change was observed in MDA levels.…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 60 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.